Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Postgrad Med
; 109(4): 115-22; quiz 9, 2001 Apr.
Article
en En
| MEDLINE
| ID: mdl-11317462
The ARBs are a new class of drugs with broad therapeutic potential in cardiovascular disease. These agents act by selectively inhibiting the AT1 subtype of the angiotensin II receptors. They are effective antihypertensive agents with promise, theoretically, in the prevention and regression of ventricular hypertrophy. They are safe and well tolerated in patients with CHF and might be effective in improving survival and reducing morbidity. ARBs also might have a similar role in improving the clinical outcomes of patients with coronary artery disease and chronic nephropathy. Their precise role in the treatment and prevention of cardiovascular and renal disease should be established by several ongoing clinical trials.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tiofenos
/
Valina
/
Angiotensina II
/
Enfermedades Cardiovasculares
/
Antagonistas de Receptores de Angiotensina
/
Enfermedades Renales
/
Antihipertensivos
Idioma:
En
Revista:
Postgrad Med
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Reino Unido